Campus

Tokyo Tokyo
Osaka Osaka
Nagoya Nagoya

Faculty & Research

Alumni Support

Healthcare Network

Since 2015, Professor Yuji Nagasawa and students in the pharmaceutical, medical, and healthcare fields at the NUCB Business School have held meetings of the Study Group for Pharmaceutical, Medical, and Healthcare Industry. This group of 345 members holds sessions after classes or on days off to discuss issues relevant to their fields. Members from various pharmaceutical, medical, and healthcare organizations, take the opportunity to share issues within their companies, or exchange information pertaining to the healthcare industry. The meetings are held at NUCB Business School locations in Tokyo, Nagoya, and Osaka, with approximately 20 to 30 members attending each meeting.

Faculty

Yuji Nagasawa

Professor

MBA, Harvard University

Venture Management, Marketing, Strategy

Yuji Nagasawa

Activity Report

  • Healthcare Network
    32nd meeting

    • Nagoya
    • Number of participants 17

    Subject

    • Why is the “Pharmacy Vision for Patients” not progressing? - What should pharmacists, who are responsible for local medical care, be like?
    • The challenge of starting a business as a pharmacist.

  • Healthcare Network
    36th meeting

    • Tokyo
    • Number of participants 26

    Subject

    • Is living a long life really happiness? ~Healthy life expectancy~
    • The path forward for domestic pharmaceutical companies.

  • Healthcare Network
    34th meeting

    • Osaka
    • Number of participants 17

    Subject

    • Should medical device manufacturers that sell products enter the solution business?
    • What are the success factors when entering the market?
    • Advice on changing jobs.
    • What are the factors behind the stalemate between generic drugs and long-listed drug businesses?

  • Healthcare Network
    35th meeting

    • Tokyo
    • Number of participants 26

    Subject

    • How should laboratories of small and medium-sized domestic pharmaceutical companies compete in the future?
    • Japan's declining birthrate and population strategy.
    • Globalization of major pharmaceutical companies and implications for Japanese companies.

VIEW ALL

Report

VIEW ALL